Why the study?
Does bevacizumab increase the risk of hypertension in patients with non-small-cell lung cancer?
Does bevacizumab increase the risk of hypertension in patients with non-small-cell lung cancer?
Bevacizumab therapy in non-small-cell lung cancer patients is associated with a markedly increased risk of developing hypertension, necessitating early monitoring and management.
Answers are grounded in this paper and cite their sources.
Bevacizumab raises hypertension risk in NSCLC; leaves open need for standardized monitoring and dose-specific trials.
AIM: A study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in non-small-cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: Electronic databases such as the Embase, PubMed, and Cochrane Library were searched for related trials. Statistical analyses were conducted to calculate the overall incidence rates, odds ratios (ORs), and 95% confidence intervals (CIs) by using either random-effect or fixed-effect models depending on the heterogeneity. RESULTS: A total of 3,155 subjects from nine studies were included. The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%-34.3%) and 6.95% (95% CI 5.81%-8.30%). Bevacizumab use was associated with a significantly increased risk in all-grade hypertension (OR 8.07, 95% CI 3.87-16.85; P=0.0002) and high-grade hypertension (OR 5.93, 95% CI 3.41-10.32; P<0.0001). No evidence of publication bias was determined for the ORs of hypertension in our meta-analysis. CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. Early monitoring and effective management of hypertension might be important steps for the safe use of this drug.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: